Cambrex Corp., an East Rutherford-based small molecule company, announced on Monday it has made changes to its management team and board of directors to “accelerate growth and further operational excellence.”
Effective immediately, they include:
- Robert Green to executive vice president and chief financial officer;
- Shawn Cavanagh to president and chief operating officer;
- Stephan Haitz to president, CDMO sales & marketing;
- The board will now be comprised of Chairman Wayne Hewett, CEO Steven Klosk, President Shawn Cavanagh, Claes Glassell, Permira’s John Coyle and Henry Minello, partners, and Laura O’Donnell, principal.
Green is succeeding Gregory Sargen, who is leaving the company on Jan. 31. Green most recently served as the chief financial officer of GE Power, the company said.
“We would like to welcome Robert to Cambrex and are excited to add someone of Robert’s caliber and experience to the senior team. On behalf of the Cambrex Board, management and employees, I would like to thank Greg Sargen for 17 years of service to Cambrex. He has had a tremendously positive impact on the company. We wish him all the best,” Wayne Hewett, chairman of the board, said.
Cavanagh has served as executive vice president and chief operating officer at Cambrex since 2011, originally joining in 1999.
“I’m proud of the depth and experience of our talented team, which is reflected in the quality of individuals transitioning to these leadership roles. We are well-positioned for continued growth in the market given our best-in-class assets, broad product capabilities and customer reputation. I’m thrilled to be working with this group of individuals and look forward to the strong future ahead,” Steven Klosk, CEO of Cambrex, said.
Haitz, who joined Cambrex in 2014, previously served as vice preisdent, sales and business development. He previously held a variety of sales and business development roles at Lonza and Solvias AG.
“I am incredibly honored to serve as Chairman during this inflection point in Cambrex’s history. The management team and Board have a remarkable combination of healthcare leadership experience and operational expertise and, following the Permira funds’ investment, are well-positioned to support Cambrex’s growth and expanded product offering to better serve leading pharmaceutical companies around the world,” Hewett said.